Carbonic anhydrase IX is a clinically significant tissue and serum biomarker associated with renal cell carcinoma

Takacova,Martina; Bartosova,Maria; Skvarkova,Lucia; Zatovicova,Miriam; Vidlickova,Ivana; Csaderova,Lucia; Barathova,Monika; Breza,Jan; Bujdak,Peter; Pastorek,Jaromir; Breza,Jan; Pastorekova,Silvia

doi:10.3892/ol.2012.1001

Carbonic anhydrase IX is a clinically significant tissue and serum biomarker associated with renal cell carcinoma

Authors:
- Martina Takacova
- Maria Bartosova
- Lucia Skvarkova
- Miriam Zatovicova
- Ivana Vidlickova
- Lucia Csaderova
- Monika Barathova
- Jan Breza
- Peter Bujdak
- Jaromir Pastorek
- Silvia Pastorekova
View Affiliations

Affiliations: Department of Molecular Medicine, Institute of Virology, Slovak Academy of Sciences, Bratislava, Slovakia, Center for Molecular Medicine, Slovak Academy of Sciences, Bratislava, Slovakia, Department of Molecular Biology, Faculty of Natural Sciences, Comenius University, Bratislava, Slovakia, Department of Urology, Derer's University Hospital, Bratislava, Slovakia
Published online on: October 26, 2012 https://doi.org/10.3892/ol.2012.1001
Pages: 191-197

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Carbonic anhydrase IX (CA IX) is regarded as one of the most prominent markers of tumor hypoxia with potential to serve as a diagnostic biomarker, prognostic indicator as well as tumor therapeutic target. The aim of the present study was to perform an in-depth analysis of CA IX expression in blood and tissue samples and to evaluate the significance of CA IX status for different renal cell carcinomas (RCCs). The expression of CA IX was determined in blood and tissue samples from 74 kidney cancer patients using reverse transcription polymerase chain reaction (RT-PCR), enzyme-linked immunosorbent assay (ELISA), Western blotting (WB) and immunohistochemistry (IHC). The CA IX status was correlated with RCC type and tumor stage. IHC and WB provided evidence for a significantly higher expression of CA IX in clear cell RCC (CCRCC) specimens compared to other RCCs. RT-PCR assay revealed that 32.42% of all RCC patients possess CA9-positive cells in peripheral blood and three-quarters of CA9-positive patients were diagnosed with CCRCC. When the patients were subdivided according to tumor stage, decreased positivity was observed with higher tumor stage (50% in T1 vs. 17% in T3). Serum CA IX levels determined by ELISA were significantly higher in CCRCC patients than in non-CCRCC. A significant association between s-CA IX and CCRCC tumor stage was also determined (T1-87.51 vs. T3-341.98 pg/ml, p=0.046). We demonstrated that the CA IX expression profiles in blood and tissue samples from 74 kidney cancer patients are closely correlated with their histological subtypes. This is the first study reporting CA IX expression in blood and tissue samples from kidney cancer patients determined by four different methods.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
2	Gnarra JR, Tory K, Weng Y, et al: Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 7:85–90. 1994. View Article : Google Scholar : PubMed/NCBI
3	Wykoff CC, Beasley NJ, Watson PH, et al: Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 60:7075–7083. 2000.PubMed/NCBI
4	Svastova E, Hulikova A, Rafajova M, et al: Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett. 577:439–445. 2004. View Article : Google Scholar : PubMed/NCBI
5	Bui MH, Seligson D, Han KR, et al: Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 9:802–811. 2003.PubMed/NCBI
6	Pastorekova S, Zavadova Z, Kostal M, Babusikova O and Zavada J: A novel quasi-viral agent, MaTu, is a two-component system. Virology. 187:620–626. 1992. View Article : Google Scholar : PubMed/NCBI
7	Zat’ovicova M, Tarabkova K, Svastova E, et al: Monoclonal antibodies generated in carbonic anhydrase IX-deficient mice recognize different domains of tumour-associated hypoxia-induced carbonic anhydrase IX. J Immunol Methods. 282:117–134. 2003.
8	Atkins M, Regan M, McDermott D, et al: Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res. 11:3714–3721. 2005. View Article : Google Scholar : PubMed/NCBI
9	Bluemke K, Bilkenroth U, Meye A, et al: Detection of circulating tumor cells in peripheral blood of patients with renal cell carcinoma correlates with prognosis. Cancer Epidemiol Biomarkers Prev. 18:2190–2194. 2009. View Article : Google Scholar : PubMed/NCBI
10	McKiernan JM, Buttyan R, Bander NH, et al: The detection of renal carcinoma cells in the peripheral blood with an enhanced reverse transcriptase-polymerase chain reaction assay for MN/CA9. Cancer. 86:492–497. 1999. View Article : Google Scholar
11	de la Taille A, Katz A, Cao Y, et al: Blood-based RT-PCR assays of MN/CA9 or PSMA: clinical application in renal cancer patients. Urology. 56:393–398. 2000.PubMed/NCBI
12	Gilbert SM, Whitson JM, Mansukhani M, et al: Detection of carbonic anhydrase-9 gene expression in peripheral blood cells predicts risk of disease recurrence in patients with renal cortical tumors. Urology. 67:942–945. 2006. View Article : Google Scholar : PubMed/NCBI
13	Ohlmann CH, Ozgur E, Schrader AJ, et al: Detection of circulating tumor cells in patients with renal cell carcinoma by reverse transcriptase polymerase chain reaction for G250/MNCA-9: results of a prospective trial. Urol Oncol. 24:287–293. 2006. View Article : Google Scholar
14	Opavsky R, Pastorekova S, Zelnik V, et al: Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics. 33:480–487. 1996. View Article : Google Scholar : PubMed/NCBI
15	Barathova M, Takacova M, Holotnakova T, et al: Alternative splicing variant of the hypoxia marker carbonic anhydrase IX expressed independently of hypoxia and tumour phenotype. Br J Cancer. 98:129–136. 2008. View Article : Google Scholar
16	Malentacchi F, Simi L, Nannelli C, et al: Alternative splicing variants of carbonic anhydrase IX in human non-small cell lung cancer. Lung Cancer. 64:271–276. 2009. View Article : Google Scholar : PubMed/NCBI
17	Malentacchi F, Vinci S, Melina AD, et al: Splicing variants of carbonic anhydrase IX in bladder cancer and urine sediments. Urol Oncol. Sep 25–2010.(Epub ahead of print).
18	Zavada J, Zavadova Z, Zat’ovicova M, Hyrsl L and Kawaciuk I: Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients. Br J Cancer. 89:1067–1071. 2003. View Article : Google Scholar : PubMed/NCBI
19	Li G, Feng G, Gentil-Perret A, Genin C and Tostain J: Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer. J Urol. 180:510–513; discussion. 513–514. 2008. View Article : Google Scholar : PubMed/NCBI
20	Zhou GX, Ireland J, Rayman P, Finke J and Zhou M: Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials. Urology. 75:257–261. 2010. View Article : Google Scholar
21	Papworth K, Sandlund J, Grankvist K, Ljungberg B and Rasmuson T: Soluble carbonic anhydrase IX is not an independent prognostic factor in human renal cell carcinoma. Anticancer Res. 30:2953–2957. 2010.PubMed/NCBI
22	Pena C, Lathia C, Shan M, Escudier B and Bukowski RM: Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin Cancer Res. 16:4853–4863. 2010. View Article : Google Scholar
23	Wind TC, Messenger MP, Thompson D, Selby PJ and Banks RE: Measuring carbonic anhydrase IX as a hypoxia biomarker: differences in concentrations in serum and plasma using a commercial enzyme-linked immunosorbent assay due to influences of metal ions. Ann Clin Biochem. 48:112–120. 2011. View Article : Google Scholar
24	Zatovicova M, Sedlakova O, Svastova E, et al: Ectodomain shedding of the hypoxia-induced carbonic anhydrase IX is a metalloprotease-dependent process regulated by TACE/ADAM17. Br J Cancer. 93:1267–1276. 2005. View Article : Google Scholar : PubMed/NCBI
25	Liao SY, Aurelio ON, Jan K, Zavada J and Stanbridge EJ: Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res. 57:2827–2831. 1997.PubMed/NCBI
26	Sandlund J, Oosterwijk E, Grankvist K, Oosterwijk-Wakka J, Ljungberg B and Rasmuson T: Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma. BJU Int. 100:556–560. 2007. View Article : Google Scholar : PubMed/NCBI
27	Patard JJ, Fergelot P, Karakiewicz PI, et al: Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer. 123:395–400. 2008. View Article : Google Scholar : PubMed/NCBI
28	Wiesener MS, Munchenhagen PM, Berger I, et al: Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res. 61:5215–5222. 2001.PubMed/NCBI